爱尔眼科: management transactions · France · AMF SZSE:300015 FR FR · AMF Mcap 102.4Bn€
Browse the full insider trade history of 爱尔眼科, a listed issuer based in France. Shares are listed on FR FR, under the authority of AMF. Market capitalisation: €102.4bn. The latest transaction was reported on 15 July 2022 — Purchase. Among the most active insiders: 吴士君. The full history is free.
Financial data FY ended December 2025 · cache
Income statement
Revenue 22.35 Bn€
Gross profit 10.53 Bn€ 47% margin
Net income 3.24 Bn€ 14.5% margin
Balance sheet & cash
Market cap 102.39 Bn€
Total debt 7.22 Bn€
Free Cash Flow 3.88 Bn€
Last declaration on 15 July 2022
Declarations 49 total
Executives ● Purchase11 SZSE
5,000 shares
SZSE:173000005689829440 · 15 Jul 2022
Ideal exit: 11 Apr 2023 (T+270) Executives ● Purchase11 SZSE
5,000 shares
SZSE:173000005681551840 · 14 Jul 2022
Ideal exit: 10 Apr 2023 (T+270) Executives ● Purchase14 SZSE
150,000 shares
SZSE:173000005649177630 · 1 Jul 2022
Ideal exit: 28 Mar 2023 (T+270) Executives ● Purchase14 SZSE
54,700 shares
SZSE:173000005641036200 · 30 Jun 2022
Ideal exit: 27 Mar 2023 (T+270) Executives ● Purchase18 SZSE
114,400 shares
SZSE:173000005614950050 · 23 Jun 2022
Ideal exit: 20 Mar 2023 (T+270) Executives ● Purchase18 SZSE
200,000 shares
SZSE:173000005610978700 · 21 Jun 2022
Ideal exit: 18 Mar 2023 (T+270) Executives ● Purchase18 SZSE
150,000 shares
SZSE:173000005605692350 · 17 Jun 2022
Ideal exit: 14 Mar 2023 (T+270) Executives ● Purchase18 SZSE
99,500 shares
SZSE:173000005599321340 · 16 Jun 2022
Ideal exit: 13 Mar 2023 (T+270) Executives ● Purchase21 SZSE
15,000 shares
SZSE:173000005595967330 · 15 Jun 2022
Ideal exit: 12 Mar 2023 (T+270) Executives ● Purchase21 SZSE
10,000 shares
SZSE:173000005585460670 · 10 Jun 2022
Ideal exit: 7 Mar 2023 (T+270) Executives ● Purchase21 SZSE
5,000 shares
SZSE:173000005581163970 · 9 Jun 2022
Ideal exit: 6 Mar 2023 (T+270) Executives ● Purchase21 SZSE
2,000 shares
SZSE:173000005578660200 · 8 Jun 2022
Ideal exit: 5 Mar 2023 (T+270) Executives ● Purchase18 SZSE
100,600 shares
SZSE:173000005564436540 · 1 Jun 2022
Ideal exit: 26 Feb 2023 (T+270) Executives ● Purchase21 SZSE
5,000 shares
SZSE:173000005564436580 · 1 Jun 2022
Ideal exit: 26 Feb 2023 (T+270) Executives ● Purchase21 SZSE
10,000 shares
SZSE:173000005560793300 · 31 May 2022
Ideal exit: 25 Feb 2023 (T+270) Executives ● Purchase21 SZSE
3,000 shares
SZSE:173000005555753570 · 27 May 2022
Ideal exit: 21 Feb 2023 (T+270) Executives ● Purchase21 SZSE
1,000 shares
SZSE:173000005552239070 · 26 May 2022
Ideal exit: 20 Feb 2023 (T+270) Executives ● Purchase21 SZSE
4,000 shares
SZSE:173000005547832130 · 24 May 2022
Ideal exit: 18 Feb 2023 (T+270) Executives ● Purchase21 SZSE
2,000 shares
SZSE:173000005545391140 · 23 May 2022
Ideal exit: 17 Feb 2023 (T+270) Executives ● Purchase21 SZSE
1,000 shares
SZSE:173000005542928000 · 20 May 2022
Ideal exit: 14 Feb 2023 (T+270) Executives ● Purchase21 SZSE
5,000 shares
SZSE:173000005522950560 · 12 May 2022
Ideal exit: 6 Feb 2023 (T+270) Executives ● Purchase21 SZSE
2,000 shares
SZSE:173000005503421700 · 29 Apr 2022
Ideal exit: 24 Jan 2023 (T+270) Executives ● Purchase21 SZSE
2,000 shares
SZSE:173000005491228640 · 28 Apr 2022
Ideal exit: 23 Jan 2023 (T+270) Executives ● Purchase21 SZSE
2,000 shares
SZSE:173000005426655680 · 25 Mar 2022
Ideal exit: 20 Dec 2022 (T+270) Executives ● Purchase33 SZSE
50,000 shares
SZSE:173000005428938720 · 24 Mar 2022
Ideal exit: 19 Dec 2022 (T+270) 25 of 49 declarations
Load more (24 remaining) About 爱尔眼科 爱尔眼科 is a company specializing in eye care in China, providing refractive surgery and treatment for eye diseases. It is listed on the XSHE market.
